The Commerce Department published notices in the June 4 Federal Register on the following AD/CV duty proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms, or effective dates will be detailed in another ITT article):
The Commerce Department issued the final results of the antidumping duty administrative review on new pneumatic off-the-road tires from China (A-570-912). Despite making changes from its preliminary results, the agency continued to find a zero AD rate for sole respondent Trelleborg Wheel Systems (Xingtai) China, Co. Ltd.. As such, Commerce will direct CBP to liquidate entries of merchandise both produced and exported Trelleborg without regard to AD duties, and will not collect AD cash deposits on such merchandise. These final results are effective June 4.
The Consumer Product Safety Commission will hold its one-day CPSC Safety Academy on Sept. 18 in Seattle, Wash. During the event, panels will discuss current commission regulatory requirements, including testing and certification, the mandatory toy standard, and compliance processes, CPSC said. One panel plans to cover the CPSC import process, it said. Requests to present in a panel discussion are due June 10. All other attendees should register by Sept. 9, CPSC said.
The Consumer Product Safety Commission is considering banning adult portable bed rails, after 62 consumer groups submitted petitions alleging the product is responsible for deaths among the elderly and frail. According to the petitioners, the bed rails can entrap and asphyxiate the elderly, and the risk of falling from climbing over the rails may be greater than the risk of falling from not having any rails at all. The petitioners claimed 155 people died because of adult portable bed rails between 2003 and 2012, CPSC said. Comments are due by Aug. 5.
On June 3 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
During the week of May 29 - June 3, the Food and Drug Administration modified the following existing Import Alerts (not otherwise listed on the FDA's new and revised import alerts page) on the detention without physical examination and/or surveillance of:
The Food and Drug Administration may refuse entry to drug products manufactured at Novartis’ Ebewe Pharma facility in Austria, alleging that a drug produced at the facility is unapproved for U.S. distribution. According to the FDA warning letter, Novartis distributed the drug without the required FDA marketing application. The agency also alleged violations of current good manufacturing practice requirements at the facility.
Food and Drug Administration export certificates for U.S. cosmetic products are now only available online, the agency said. Beginning June 3, paper cosmetic export certificates are no longer available. According to the FDA, the switch from a paper-based system to a web-based system will make the application process more efficient for exporters and the agency. Export certificates are provided to foreign importers of U.S. cosmetic products, and may be required by foreign governments. Certificates are available through the FDA Certificate Application Process website. Exporters can create an account (here). An example of the new certificates and the new “Certificate Identifier” are (here). Frequently asked questions on cosmetic export certificates are (here).
The Food and Drug Administration will continue to refuse entry of a drug product packaged at Contract Pharmaceutical Services of Australia’s North Ryde facility, it said in a warning letter. A previous FDA inspection found current good manufacturing practice violations that still haven’t been corrected, and the firm also failed to register, the agency said. FDA redacted the name of the drug subject to import refusal in the letter.
On June 3, the Foreign Agricultural Service posted the following GAIN reports: